You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)榮獲2019年度國家科學技術進步獎
格隆匯 01-17 12:04

格隆匯1月17日丨中國生物製藥(01177.HK)公佈,公司附屬公司北京泰德製藥股份有限公司聯合北京大學申報的"藥物新制劑中乳化關鍵技術體系建立與應用"科研項目榮獲"2019年度國家科學技術進步獎二等獎",集團成為獲獎的為數不多的製藥企業之一。

公告顯示,國家科學技術進步獎,是中國國務院設立的國家科學技術獎五大獎項之一,主要授予在技術研究、技術開發、技術創新、推廣應用先進科學技術成果、促進高新技術產業化,以及完成重大科學技術工程、計劃等過程中做出創造性貢獻的中國公民和組織。此次獲獎是對集團的乳化高端製劑研發平台的高度認可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account